Is Whole‐Brain Radiotherapy for Brain Metastases an Overestimated Therapy?
Author Information
Author(s): Florian Hoelzl, Oliver Koelbl, Isabella Gruber
Primary Institution: University Hospital of Regensburg
Hypothesis
The study aims to evaluate the effectiveness and patient selection for whole-brain radiotherapy in patients with brain metastases.
Conclusion
One-third of patients treated with whole-brain radiotherapy died within 90 days, indicating the need for better patient selection, although neurological symptoms improved with treatment.
Supporting Evidence
- Median survival was 4.3 months for all patients after whole-brain radiotherapy.
- Patients receiving immunotherapy had a median survival of 6.4 months compared to 3.1 months for those who did not.
- 36.5% of patients died within the first 90 days after treatment.
Takeaway
This study looked at patients with brain cancer who got a specific type of radiation treatment. It found that many patients didn't live long after the treatment, so doctors need to be more careful about who gets this treatment.
Methodology
The study analyzed data from 285 patients who received whole-brain radiotherapy, using Cox regression analyses and landmark analyses to assess survival and neurological symptoms.
Potential Biases
Potential bias due to the retrospective nature and selection of patients who may not represent the broader population.
Limitations
The study is limited by its retrospective design and lack of a comparison group for best supportive care.
Participant Demographics
Median age was 62 years, with a mix of cancer types including non-small cell lung cancer, breast cancer, and small cell lung cancer.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 0.356–0.606
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website